

8th Adriatic and 5th ISPOR Chapter Serbia Congress on Pharmacoeconomics and Outcomes Research

Improving Patients' Health Outcomes by Fair, Transparent and Affordable Access to New Technologies'

THURSDAY (19.4.2018)

Opening ceremony

[Welcome address by Congress President, Dragana Atanasijevic](#)

[Welcome address by Congress President, Dinko Vitezic](#)

Welcome address by Secretary of State at Serbian Ministry of Health, Meho Mahmutovic

Welcome address by Director of Serbian Health Insurance Fund

Welcome address by WHO representative for Serbia, Zsofia Pusztai

Welcome address by Programme officer - EU policies / programming / health / floods and DRM coordinator - European Union Delegation to the Republic of Serbia - European Commission, Maja Vuckovic Krcmar

Importance of continuous health economics and outcomes research education for the sustainability of healthcare financing and patients wellbeing

Chairmen: Dragana Atanasijevic, Dinko Vitezic

[FR Francois Meyer: Importance of continuous health economics and outcomes research education for the sustainability of healthcare financing and patients wellbeing](#)

[HU Zoltan Kalo: Where science and policy meet: Allocation and efficiency of healthcare with special focus on CEE countries](#)

[SRB Goran Stevanovic: Health economic and patients outcomes aspects of antimicrobial resistance: what should we do to improve?](#)

[SI Rok Hren: ISPOR Health Science Policy Council support to the ISPOR community and its research activities in the region](#)

Sustainability of health care financing through DRG; The role of hospital management in the utilization of health economics in decision making

Chairmen: SRB TBC, HR Sinisa Varga

[TK Rabia Kahveci: Can we ensure value and improve performance by linking clinical quality and HTA?](#)

[HU Ferenc Kohalmi: Hungarian DRG - the Road from Introduction to 25 Years of Use](#)

[HR Davor Katavic: Sustainability of healthcare financing in Croatia](#)

[SRB Simo Vukovic: Introduction of performance based payment in Serbia](#)

Round table discussion:

- The role of hospital management in the utilization of health economic and quality standards in decision making;
- Health economic aspects of DRG implementation in CEE

Moderator: HR Sinisa Varga

Faculty: (1) SRB MoH TBC, (2) SRB HIF TBC, (3) HR Tihomir Strizrep, (4) RO Laszlo Lorenzovici, (5) BIH-RS Sinisa Stevic, (6) BIH-RS Djajic, (7) MN MoH TBC

FRIDAY (20.4.2018)

Antimicrobial resistance: influencing factors, economic and organizational implications

Chairmen: SRB Ljiljana Pavlovic, HR Aleksandar Knezevic

[SRB Vesela Radonjic: Surveillance of antibiotic use in Serbia](#)

[PO Krzysztof Łanda: Pricing and economic tools for rational evaluation and rationing of antibiotics utilization in modern health care](#)

[HR Iva Kraljickovic: Impact of piperacillin / tazobactam shortage in 2017 on overall antibiotic expenditure at the University hospital center Zagreb](#)

[SRB Vesna Suljagic: Is Antibiotic Overuse a Major Risk Factor for Clostridium difficile Infection in Surgical Patients?](#)

[RO Adrian Pana: A Cost Minimization Analysis of a novel antibiotic vs SoC for the treatment of ABSSSI in Romania: resources and organizational outlooks](#)

Importance of strategic collection and analysis of health data to improve quality and transparency of decision making processes

Chairmen: SRB TBC, SI Natalija Petkovic

[SRB Daria Kisic Tepavcevic: Quality of life measures - tool for decision makers](#)

[Livio Garattini \(IT\): Immunotherapies for advanced melanoma: as promising as they are expensive?](#)

[HR Sinisa Varga: eHealth, BIG DATA](#)

[SRB Dragana Atanasijevic: Using data to drive decisions - from prioritization to health care expenses](#)

BG Desislava Mihaylova: Big DATA in Oncology

[HR Zvonimir Durriql: From pharmacokinetics to Real-World evidence – an example of different data sources for value based](#)

Value based pricing and reimbursement policies; how to improve access to new technologies?

Chairmen: SRB TBC, HR Slobodanka Bolanca

[A Thomas Griesbacher: Uptake of biosimilar products in Austria in relation to new legislation and the availability of new biosimilars](#)

[HU András Harsányi: Biosimilar drug policy in Hungary: Evaluating the results through infliximab's patent expiry](#)

[HR Pero Draganic: Biosimilar medicines in Croatia and some CEE countries: determining the price and recompense](#)

[SI Andrej Janzic: Understanding and relevance of criteria for reimbursement decision-making process](#)

[SRB Vlad Zah: "How to connect healthcare reimbursement claims analyses to drive value based pricing decisions"](#)

[BE Omer Saka: Road to Value in Bulgaria](#)

Future of HTA in CEE – 'nice to have' or 'must have'? Readiness of CEE national health administrations to fairly assess diverse new technologies

Chairmen: SRB Dragana Atanasijevic, HU Zoltan Kalo

[FR Mira Pavlovic: Health Economic Evidence required for a meaningful reimbursement: reflection from HAS France](#)

[US Jonathan D Campbell: Value Frameworks and US HTA Implementation](#)

[HR Luka Voncina: HTA policy assessment in South East Europe - how to fix the gap?](#)

[HR Drazen Jelec: Joint initiative to advance access to innovative medicines in the EU](#)

Round table discussion:

- Readiness and capacity of national health administration in CEE countries to fairly assess / appraise diverse new technologies; Roles and responsibilities of different stakeholders in Healthcare (e.g. Health administration, Professional associations, Patient Associations, etc)

- Future of HTA in CEE – 'nice to have' or 'must have'?

Moderator: HU Zoltan Kalo

Faculty: (1) SRB MoH TBC, (2) SRB HIF / NIPH TBC, (3) TK Rabia Kahveci, (4) HU András Harsányi, (5) BG Guenka Petrova, (6) FR Francois Meyer, (7) HR Tea Strbad

SATURDAY (21.4.2018)

Specifics of health economic studies in different therapeutic areas (COPD and Diabetes)

Chairmen: SRB TBC, BG Guenka Petrova

[BG Maria Kamusheva, Konstantin Tachkov, Miglena Doneva, Valentina](#)

[Petkova, Alexandra Savova, Konstantin Mitov, Guenka Petrova: Epidemiology and cost of COPD therapy in Bulgaria](#)

[BG Konstantin Tachkov: Modelling the long term cost and results of COPD therapy](#)

[PO Maciej Niewada: Cost of cardiovascular diseases in diabetic patients in selected Central and Eastern European countries](#)

[SI Karmen Janša: Overview of cardiovascular disease burden in patients with diabetes in Slovenia](#)

[PO Michał Jakubczyk: Cost of severe hypoglycaemia in selected European countries](#)

[SRB: Miodrag Bogdanovic: Cost-utility evaluation of new generation basal insulins](#)

Sustainability of patient access to orphan drugs in CEE

Chairmen: SRB TBC, HR Iva Kraljickovic

[HR Dinko Vitezic: Orphan medicines: where are we now?](#)

[SRB Davor Duboka: Patient access to orphan drugs and potential improvements](#)

[SI Andreja Deticek: Access of medicines for rare diseases in EU/CEE countries](#)

[\(MK\) Biljana Indova, Ljubica Shuturkova, Rubin Zareski, Zoran Sterjev \(MK\): Clinical and economic impact of introduction of adalimumab in treatment of RA patients in R.Macedonia](#)

[GE Marko Obradovic: Use of real-world data to improve access to new technologies](#)

Equity and equality of patient access to oncology treatments in CEE

Chairmen: SRB TBC, MK Ljubica Suturkova

[SRB Dragan Loncar/Filip Stojanovic: Availability of oncology treatments](#)

[Nika Mardjetko, Andreja Deticek, Andrej Janzic, Igor Locatelli, Mitja Kos \(SI\): Access to new anticancer medicines in EU/CEE](#)

[Eve Hanna, Mondher Toumi, Claude Dussart, Borislav Borissov \(BG\), Olivier Dabbous, Karolina Badora, Pascale Auquier: Funding breakthrough therapies – a systematic review and recommendations](#)

[Marija Seistrajkova \(MK\): Expensive drugs for hospital use in Macedonia - Pandora's box for health insurance](#)

Legislative framework for co-financing arrangement for innovative health technologies - how could we move forward in CEE?

Chairmen: SRB TBC, HU Bertalan Nemeth

[PO Katarzyna Kolasa: Do's and Don'ts for the implementation of innovative pricing&reimbursement models- key learnings from financing schemes of pharmaceutical and medical devices across EU settings](#)

[SRB Dragana Janjic: Health policies development & complexities of break through innovation: DOES ONE SIZE FIT ALL?](#)

HR Slobodanka Bolanca: Which criteria play a major role in the feasibility and success of MEA implementation in SEE

[SRB Bojan Trkulja: Legislative obstacles and possible solutions for better access to innovation](#)

Round table discussion:

Major legislative and operational hurdles in effective implementation of co-financing and affordability programs in CEE

Moderator: HU Bertalan Nemeth

Faculty: (1) SRB MOH (2) SRB RFZO, (3) IT Livio Garattini, (4) HR Luka Voncina, (5) BIH-RS Natasa Grubisa, (6) MN TBC, (7) MK TBC

Congress Closing